Physician profile
Michael S Blank
NPI 1710926985
$3,313.61
in general payments reported to CMS, 2019-2025
9 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what 79% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.30 · 2020: $39.61 · 2021: $76.77 · 2022: $200 · 2023: $975 · 2024: $867 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,900 · Education: $10.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,899.85 |
| Education | $10.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,453.19 | 2022-2025 | Descovy, Biktarvy, Veklury |
| Viiv Healthcare Company | $616.47 | 2022-2025 | Dovato, Apretude |
| Abbvie INC. | $485.26 | 2021-2025 | Avycaz, Dalvance, Teflaro |
| Merck Sharp & Dohme LLC | $391.89 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Aimmune Therapeutics, INC. | $213.34 | 2024-2025 | Vowst |
| Ferring Pharmaceuticals INC. | $83.56 | 2023-2025 | Rebyota |
| Allergan, INC. | $38.50 | 2019-2020 | |
| Insmed, INC. | $16.43 | 2025 | Arikayce |
| Paratek Pharmaceuticals, INC. | $14.97 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Blank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.